| Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real-world retrospective study |
|
European Journal of Haematology |
Aplastic Anemia |
| Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy |
|
Haematologica |
Aplastic Anemia |
| Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment |
|
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes |
|
Current Treatment Options in Oncology |
Myelodysplastic Syndromes (MDS) |
| The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances |
|
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age |
|
Blood Reviews |
Myelodysplastic Syndromes (MDS) |
| Overview of the Management of Higher-Risk Myelodysplastic Syndromes |
|
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| Epidemiology and Pathogenesis of Myelodysplastic Syndrome |
|
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
